Cumulative incidence of false-positive results in repeated, multimodal cancer screening

Annals of Family Medicine

Volumn 7, Issue 3, 2009, Pages 212-222

  Croswell, Jennifer Miller ^a   Kramer, Barnett S ^a   Kreimer, Aimee R ^b   Prorok, Phil C ^m   Xu, Jian Lun ^b   Baker, Stuart G ^b   Fagerstrom, Richard ^b   Riley, Thomas L ^c   Clapp, Jonathan D ^c   Berg, Christine D ^b   Gohagan, John K ^b   Andriole, Gerald L ^d   Chia, David ^e   Church, Timothy R ^f   Crawford, E David ^g   Fouad, Mona N ^h   Gelmann, Edward P ⁱ   Lamerato, Lois ^j   Reding, Douglas J ^k   Schoen, Robert E ^l  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c IMS Incorporated   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ Och Spine at New York Presbyterian Hospitals   (United States)

^j HENRY FORD HEALTH SYSTEM   (United States)

^k MARSHFIELD CLINIC   (United States)

^l UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^m NONE

more..

Author keywords

False positive reactions; Mass screening; Neoplasms; Randomized controlled trial

Indexed keywords

CA 125 ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; FALSE POSITIVE RESULT; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIGMOIDOSCOPY; THORAX RADIOGRAPHY; TRANSVAGINAL ECHOGRAPHY;

EID: 67249153691     PISSN: 15441709     EISSN: 15441717     Source Type: Journal    
DOI: 10.1370/afm.942     Document Type: Article

References (38)

1. Lung Cancer Alliance. Lung cancer screening and early detection. http://www.lungcanceralliance.org/facing/screening.html. Accessed Apr 24, 2008.
2. American Urological Association. Prostate cancer screening. http:// www.urologyhealth.org/adult/index.cfm?cat=05&topic=250. Accessed Apr 24, 2008.
3. Centers for Disease Control and Prevention. Colorectal (colon) cancer. Screening guidelines. http://www.cdc.gov/cancer/colorectal/ basic-info/ screening/guidelines.htm. Accessed Apr 24, 2008.
4. Armstrong JT, Brandt K, Read Y. Women's Health Screening in Napa Valley: Uterine, Tube, and Ovarian Screening. http://www. womenshealthscreening.com/ pelvic.htm. Accessed Apr 24, 2008.
5. American Cancer Society. American Cancer Society guidelines for the early detection of cancer. http://www.cancer.org/docroot/ PED/content/PED-2-3X-ACS- Cancer-Detection-Guidelines- 36.asp?sitearea=PED. Accessed Apr 24, 2008.
6. National Cancer Institute. The Pap test: questions and answers. http://www.cancer.gov/cancertopics/factsheet/detection/Pap-test. Accessed Apr 24, 2008.
7. The Skin Cancer Foundation. Early detection. The ugly duckling sign: an early melanoma detection tool. http://www.skincancer.org/ early-detection/. Accessed Apr 24, 2008.
8. Bladder Cancer Screening Underway in Communities across the Country Using the NMP22(R) BladderChek(R) Test. Business Wire. http://goliath.ecnext.com/ coms2/gi-0199-5732062/Bladder-Cancer- Screening-Underway-in.html. Accessed Apr 24, 2008.
9. Meyskens FL. Cancer prevention, screening, and early detection. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical Oncology. 3rd ed. Amsterdam: Elsevier Publishing; 2004.
10. Brawley OW, Kramer BS. Cancer screening in theory and in practice. J Clin Oncol. 2004;23(2):293-300. (Pubitemid 46206880)
11. Lafata JE, Simpkins J, Lamerato L, et al. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2126-2132. (Pubitemid 40054307)
12. Brewer NT, Salz T, Lillie SE. Systematic review: the long-term effects of false-positive mammograms. Ann Intern Med. 2007;146(7):502-510. (Pubitemid 351650559)
13. Gilbert FJ, Cordiner CM, Affleck IR, et al. Breast screening: the psychological sequelae of false-positive recall in women with and without a family history of breast cancer. Eur J Cancer. 1998;34(13):2010-2014. (Pubitemid 28546933)
14. Elmore JG, Barton MB, Moceri VM, et al. Ten-year risk of FP screening mammograms and clinical breast examinations. N Engl J Med. 1998;338(16):1089- 1096. (Pubitemid 28227478)
15. Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian breast cancer screening program. Cancer. 2004;101(7):1501-1507. (Pubitemid 39318894)
16. Christiansen CL, Wang F, Barton MB, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 2000;92(20):1657-1666. (Pubitemid 30807646)
17. Njor SH, Olsen AH, Schwartz W, Vejborg I, Lynge E. Predicting the risk of a false-positive test for women following a mammography screening programme. J Med Screen. 2007;14(2):94-97. (Pubitemid 47067764)
18. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6)(Suppl):273S-309S.
19. Gohagan JK, Prorok PC, Hayes RB, Kramer BS. The prostate, lung, colorectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6)(Suppl):251S-272S.
20. O'Brien B, Nichaman L, Browne JE, et al. Coordination and management of a large multicenter screening trial: the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6)(Suppl):310S-328S.
21. Hasson MA, Fagerstrom RM, Kahane DC, et al. Design and evolution of the data management systems in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6)(Suppl):329S-348S.
22. Weissfeld JL, Fagerstrom RM, O'Brien B. Quality control of cancer screening examination procedures in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6)(Suppl):390S-399S.
23. Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK. The prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: status and promise. Urol Oncol. 2004;22(4):358-361. (Pubitemid 38993317)
24. Pavlik EJ, DePriest PD, Gallion HH, et al. Ovarian volume related to age. Gynecol Oncol. 2000;77(3):410-412. (Pubitemid 30368559)
25. Rex DK, Ransohoff DF, Achkar E. Colonoscopy is justified for any polyp discovered during computed tomographic colonography. Am J Gastroenterol. 2005;100(9):1903-1908. (Pubitemid 43919379)
26. Ransohoff DF. Colon cancer screening in 2005: status and challenges. Gastroenterology. 2005;128(6):1685-1695.
27. Xu JL, Fagerstrom RM, Prorok PC, Kramer BS. Estimating the cumulative risk of a false-positive test in a repeated screening program. Biometrics. 2004;60(3):651-660. (Pubitemid 39181109)
28. Baker SG, Kramer BS. Estimating the cumulative risk of a false-positive under a regimen involving various types of cancer screening tests. J Med Screen. 2008;15(1):18-22. (Pubitemid 351629541)
29. Pinsky PF, Miller A, Kramer BS. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol. 2007;165(8):874-881. (Pubitemid 46536660)
30. Tornblom M, Erikson H, Franzen S, et al. Lead time associated with screening for prostate cancer. Int J Cancer. 2004;108(1):122-129. (Pubitemid 37444454)
31. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet. 2002;359(9314):1291-1300. (Pubitemid 34310634)
32. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy "- SCORE. J Natl Cancer Inst. 2002;94(23):1763-1772.
33. Weissfeld JL, Schoen RE, Pinsky PF, et al. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst. 2005;97(13):989-997.
34. Gross CP, Andersen MS, Krumholz HM, et al. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. JAMA. 2006;296(23):2815-2822. (Pubitemid 44969181)
35. Seeff LC, Richards TB, Shapiro JA, et al. How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. Gastroenterology. 2004;127(6):1670-1677. (Pubitemid 39575845)
36. US Preventive Services Task Force. Screening for colorectal cancer: recommendations and rationale. Rockville, MD: Agency for Healthcare Research and Quality; 2002. http://www.ahrq.gov/clinic/3rduspstf/colorectal/colorr.htm. Accessed Jul 22, 2008.
37. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58(3):130-160.
38. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1):66-70. (Pubitemid 41002840)